What is Osanni Bio?
Osanni Bio operates at the intersection of advanced biotechnology and therapeutic development. The company is dedicated to building a next-generation platform designed to identify and advance novel drug candidates. By leveraging a sophisticated discovery engine, Osanni Bio targets high-impact therapeutic areas, including ophthalmology and cardiology. Its market position is defined by a commitment to addressing complex medical needs through rigorous scientific inquiry, effectively bridging the gap between theoretical drug concepts and actionable clinical development programs. The firm's strategic focus on high-unmet-need sectors positions it as a critical player in the evolving landscape of modern medicine.
How much funding has Osanni Bio raised?
Osanni Bio has raised a total of $190M across 1 funding round:
Series B
$190M
Series B (2026): $190M with participation from Horowitz Group, Invus, Retinal Degeneration Fund, and Patient Square Capital
Key Investors in Osanni Bio
Horowitz Group
A Southern California-based single family office that provides patient capital through opportunistic minority and control equity investments across diverse sectors including healthcare.
Invus
A New York-based investment firm established in 1985, providing comprehensive financial advisory and strategic consulting services to support long-term business growth.
Retinal Degeneration Fund
A specialized fund focused on accelerating life-changing therapeutic outcomes for retinal degenerative diseases in collaboration with the Foundation Fighting Blindness.
What's next for Osanni Bio?
With the infusion of this recent capital, Osanni Bio is poised to scale its development programs significantly. The strategic roadmap likely involves expanding its clinical trial infrastructure and deepening its research capabilities in ophthalmology and cardiology. As the company matures, the focus will shift toward validating its drug candidates through regulatory milestones and potential commercial partnerships. The involvement of specialized healthcare investors suggests a long-term commitment to building a sustainable, high-value pipeline that could redefine standards of care in its target therapeutic fields. Future growth will be contingent upon the successful translation of its discovery engine outputs into viable, patient-centric medical solutions.
See full Osanni Bio company page
